ReviewPharmacoEconomics2014
A review of the economics of treating Clostridium difficile infection.
Review in PharmacoEconomics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Cost-Effectiveness of Competing Treatment Strategies for Clostridium difficile Infection: A Systematic Review.Infection control and hospital epidemiology · 2018Pooled it
- Cost of hospital management of Clostridium difficile infection in United States-a meta-analysis and modelling study.BMC infectious diseases · 2016Pooled it
- Review
- Nitro-Group-Containing Thiopeptide Derivatives as Promising Agents to TargetPharmaceuticals (Basel, Switzerland) · 2022Article
- Article
- A new role for heat shock factor 27 in the pathophysiology ofAmerican journal of physiology. Gastrointestinal and liver physiology · 2020Article
- Proteomic Signatures ofCells · 2018Article
- Comprehensive Redox Profiling of the Thiol Proteome ofMolecular & cellular proteomics : MCP · 2018Article
- An Engineered Synthetic Biologic Protects AgainstFrontiers in microbiology · 2018Article
- Adherence to clinical practice guidelines for the management of Clostridium difficile infection in Japan: a multicenter retrospective study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2017Observational
- Rapid change of fecal microbiome and disappearance of Clostridium difficile in a colonized infant after transition from breast milk to cow milk.Microbiome · 2016Article
- CRISPR Diversity and Microevolution in Clostridium difficile.Genome biology and evolution · 2016Article
- Clostridium Difficile Infection from a Surgical Perspective.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2015Review
- The Clostridium difficile Protease Cwp84 Modulates both Biofilm Formation and Cell-Surface Properties.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clostridium difficile infection (CDI) is a costly result of antibiotic use, responsible for an estimated 14,000 deaths annually in the USA according to the Centers for Disease Control and Prevention. Annual costs attributable to CDI are in excess of $US 1 billion. This review summarizes appropriate utilization of prevention and treatment methods for CDI that have the potential to reduce the economic and humanistic costs of the disease. Some cost-effective strategies to prevent CDI include screening and isolation of hospital admissions based on C. difficile carriage to reduce transmission in the inpatient setting, and probiotics, which are potentially efficacious in preventing CDI in the appropriate patient population. The most extensively studied agents for treatment of CDI are metronidazole, vancomycin, and fidaxomicin. Most economic comparisons between metronidazole and vancomycin favor vancomycin, especially with the emergence of metronidazole-resistant C. difficile strains. Metronidazole can only be recommended for mild disease. Moderate to severe CDI should be treated with vancomycin, preferably the compounded oral solution, which provides the most cost-effective therapeutic option. Fidaxomicin offers a clinically effective and potentially cost-effective alternative for treating moderate CDI in patients who do not have the NAP1/BI/027 strain of C. difficile. Probiotics and fecal microbiota transplant have variable efficacy and the US FDA does not currently regulate the content; the potential economic advantages of these treatment modalities are currently unknown.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.